Which has stronger earnings and valuation, INDV or ARDX?

Indivior has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indivior $1.24B 3.94 $210M $1.95 20.52 Ardelyx $407.32M 3.00 -$61.60M -$0.23 N/A

Is INDV or ARDX more profitable?

Indivior has a net margin of 19.44% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets Indivior 19.44% -219.26% 29.40% Ardelyx -13.58% -38.11% -11.85%

Does the media prefer INDV or ARDX?

In the previous week, Ardelyx had 4 more articles in the media than Indivior. MarketBeat recorded 7 mentions for Ardelyx and 3 mentions for Indivior. Indivior's average media sentiment score of 0.95 beat Ardelyx's score of 0.74 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KNSA or ARDX?

In the previous week, Kiniksa Pharmaceuticals International had 29 more articles in the media than Ardelyx. MarketBeat recorded 36 mentions for Kiniksa Pharmaceuticals International and 7 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.74 beat Kiniksa Pharmaceuticals International's score of 0.66 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 12 Very Positive mention(s) 1 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MANE or ARDX more profitable?

Veradermics has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Veradermics' return on equity of 0.00% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A Ardelyx -13.58% -38.11% -11.85%

Does the media prefer MANE or ARDX?

In the previous week, Ardelyx had 5 more articles in the media than Veradermics. MarketBeat recorded 7 mentions for Ardelyx and 2 mentions for Veradermics. Ardelyx's average media sentiment score of 0.74 beat Veradermics' score of 0.42 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ardelyx 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DYN or ARDX?

In the previous week, Dyne Therapeutics had 16 more articles in the media than Ardelyx. MarketBeat recorded 23 mentions for Dyne Therapeutics and 7 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.74 beat Dyne Therapeutics' score of 0.63 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 11 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, CRSP or ARDX?

Ardelyx has higher revenue and earnings than CRISPR Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CRISPR Therapeutics $3.51M 1,318.70 -$581.60M -$6.22 N/A Ardelyx $407.32M 3.00 -$61.60M -$0.23 N/A

Does the media favor CRSP or ARDX?

In the previous week, Ardelyx had 2 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 7 mentions for Ardelyx and 5 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.90 beat Ardelyx's score of 0.74 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ardelyx (ARDX) Competitors

$4.95 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$4.94 0.00 (-0.10%)

As of 07/31/2026 07:34 PM Eastern

Compare

ARDX vs. INDV, KNSA, MANE, DYN, and CRSP

Should you buy Ardelyx stock or one of its competitors? MarketBeat compares Ardelyx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ardelyx include Indivior (INDV), Kiniksa Pharmaceuticals International (KNSA), Veradermics (MANE), Dyne Therapeutics (DYN), and CRISPR Therapeutics (CRSP).

How does Ardelyx compare to Indivior?

Indivior (NASDAQ:INDV) and Ardelyx (NASDAQ:ARDX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Indivior presently has a consensus target price of $43.67, suggesting a potential upside of 9.14%. Ardelyx has a consensus target price of $15.73, suggesting a potential upside of 217.72%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts plainly believe Ardelyx is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Indivior has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

Indivior has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.94	$210M	$1.95	20.52
Ardelyx	$407.32M	3.00	-$61.60M	-$0.23	N/A

Indivior has a net margin of 19.44% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Ardelyx	-13.58%	-38.11%	-11.85%

In the previous week, Ardelyx had 4 more articles in the media than Indivior. MarketBeat recorded 7 mentions for Ardelyx and 3 mentions for Indivior. Indivior's average media sentiment score of 0.95 beat Ardelyx's score of 0.74 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

60.3% of Indivior shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 0.7% of Indivior shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Indivior beats Ardelyx on 10 of the 17 factors compared between the two stocks.

How does Ardelyx compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Ardelyx (NASDAQ:ARDX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$840.85M	6.80	$59.01M	$0.97	76.64
Ardelyx	$407.32M	3.00	-$61.60M	-$0.23	N/A

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Ardelyx's net margin of -13.58%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%
Ardelyx	-13.58%	-38.11%	-11.85%

In the previous week, Kiniksa Pharmaceuticals International had 29 more articles in the media than Ardelyx. MarketBeat recorded 36 mentions for Kiniksa Pharmaceuticals International and 7 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.74 beat Kiniksa Pharmaceuticals International's score of 0.66 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	12 Very Positive mention(s)	1 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International presently has a consensus target price of $87.38, suggesting a potential upside of 17.53%. Ardelyx has a consensus target price of $15.73, suggesting a potential upside of 217.72%. Given Ardelyx's higher probable upside, analysts clearly believe Ardelyx is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Kiniksa Pharmaceuticals International has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Kiniksa Pharmaceuticals International beats Ardelyx on 11 of the 16 factors compared between the two stocks.

How does Ardelyx compare to Veradermics?

Veradermics (NYSE:MANE) and Ardelyx (NASDAQ:ARDX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Veradermics has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Veradermics' return on equity of 0.00% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Ardelyx	-13.58%	-38.11%	-11.85%

In the previous week, Ardelyx had 5 more articles in the media than Veradermics. MarketBeat recorded 7 mentions for Ardelyx and 2 mentions for Veradermics. Ardelyx's average media sentiment score of 0.74 beat Veradermics' score of 0.42 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ardelyx	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

58.9% of Ardelyx shares are held by institutional investors. 5.3% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Veradermics currently has a consensus price target of $153.00, indicating a potential upside of 45.65%. Ardelyx has a consensus price target of $15.73, indicating a potential upside of 217.72%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts plainly believe Ardelyx is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Veradermics has higher earnings, but lower revenue than Ardelyx. Veradermics is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	N/A	-$1.32	N/A
Ardelyx	$407.32M	3.00	-$61.60M	-$0.23	N/A

Summary

Ardelyx beats Veradermics on 11 of the 14 factors compared between the two stocks.

How does Ardelyx compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Ardelyx (NASDAQ:ARDX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Dyne Therapeutics has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

Dyne Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
Ardelyx	-13.58%	-38.11%	-11.85%

In the previous week, Dyne Therapeutics had 16 more articles in the media than Ardelyx. MarketBeat recorded 23 mentions for Dyne Therapeutics and 7 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.74 beat Dyne Therapeutics' score of 0.63 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	11 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ardelyx has higher revenue and earnings than Dyne Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
Ardelyx	$407.32M	3.00	-$61.60M	-$0.23	N/A

Dyne Therapeutics presently has a consensus target price of $34.42, indicating a potential upside of 36.68%. Ardelyx has a consensus target price of $15.73, indicating a potential upside of 217.72%. Given Ardelyx's higher possible upside, analysts clearly believe Ardelyx is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Dyne Therapeutics beats Ardelyx on 9 of the 16 factors compared between the two stocks.

How does Ardelyx compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Ardelyx (NASDAQ:ARDX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

CRISPR Therapeutics currently has a consensus price target of $67.78, indicating a potential upside of 41.23%. Ardelyx has a consensus price target of $15.73, indicating a potential upside of 217.72%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Ardelyx had 2 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 7 mentions for Ardelyx and 5 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.90 beat Ardelyx's score of 0.74 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ardelyx has a net margin of -13.58% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Ardelyx	-13.58%	-38.11%	-11.85%

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CRISPR Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

Ardelyx has higher revenue and earnings than CRISPR Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,318.70	-$581.60M	-$6.22	N/A
Ardelyx	$407.32M	3.00	-$61.60M	-$0.23	N/A

Summary

Ardelyx beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Ardelyx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARDX vs. The Competition

Export

Metric	Ardelyx	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.22B	$11.71B	$6.86B	$12.42B
Dividend Yield	N/A	2.72%	2.59%	10.03%
P/E Ratio	-21.52	799.05	282.30	24.66
Price / Sales	3.00	752.17	561.34	76.65
Price / Cash	N/A	14.82	28.60	46.71
Price / Book	7.17	10.36	10.98	6.07
Net Income	-$61.60M	$2.82B	$3.49B	$347.99M
7 Day Performance	-2.17%	-0.10%	-0.60%	-0.44%
1 Month Performance	-6.07%	-3.96%	-5.20%	-4.81%
1 Year Performance	14.32%	156.17%	62.01%	18.61%

Ardelyx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARDX Ardelyx	2.5504 of 5 stars	$4.95 flat	$15.73 +217.7%	+14.3%	$1.22B	$407.32M	N/A	90	Upcoming Earnings
INDV Indivior	2.5208 of 5 stars	$40.03 -1.2%	$43.67 +9.1%	+90.1%	$4.94B	$1.24B	20.53	1,051	Upcoming Earnings
KNSA Kiniksa Pharmaceuticals International	4.0082 of 5 stars	$63.53 +1.1%	$68.00 +7.0%	+132.5%	$4.83B	$677.56M	70.59	220	Earnings Report Insider Trade
MANE Veradermics	2.2953 of 5 stars	$111.63 +1.9%	$153.00 +37.1%	N/A	$4.66B	N/A	N/A	19	Analyst Upgrade Lockup Expiration
DYN Dyne Therapeutics	3.4241 of 5 stars	$25.63 +4.9%	$34.17 +33.3%	+150.5%	$4.56B	N/A	N/A	100	Earnings Report Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARDX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ardelyx (ARDX) Competitors

ARDX vs. INDV, KNSA, MANE, DYN, and CRSP

How does Ardelyx compare to Indivior?

Summary

How does Ardelyx compare to Kiniksa Pharmaceuticals International?

Summary

How does Ardelyx compare to Veradermics?

Summary

How does Ardelyx compare to Dyne Therapeutics?

Summary

How does Ardelyx compare to CRISPR Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX vs. The Competition

Ardelyx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ardelyx (ARDX) Competitors

ARDX vs. INDV, KNSA, MANE, DYN, and CRSP

How does Ardelyx compare to Indivior?

Do analysts prefer INDV or ARDX?

Which has more risk & volatility, INDV or ARDX?

Which has stronger earnings and valuation, INDV or ARDX?

Is INDV or ARDX more profitable?

Does the media prefer INDV or ARDX?

Do insiders and institutionals hold more shares of INDV or ARDX?

Summary

How does Ardelyx compare to Kiniksa Pharmaceuticals International?

Which has higher earnings & valuation, KNSA or ARDX?

Is KNSA or ARDX more profitable?

Does the media prefer KNSA or ARDX?

Do analysts prefer KNSA or ARDX?

Which has more volatility and risk, KNSA or ARDX?

Do institutionals and insiders hold more shares of KNSA or ARDX?

Summary

How does Ardelyx compare to Veradermics?

Is MANE or ARDX more profitable?

Does the media prefer MANE or ARDX?

Do insiders and institutionals hold more shares of MANE or ARDX?

Do analysts prefer MANE or ARDX?

Which has preferable valuation & earnings, MANE or ARDX?

Summary

How does Ardelyx compare to Dyne Therapeutics?

Which has more risk and volatility, DYN or ARDX?

Is DYN or ARDX more profitable?

Does the media favor DYN or ARDX?

Do insiders & institutionals hold more shares of DYN or ARDX?

Which has stronger valuation and earnings, DYN or ARDX?

Do analysts prefer DYN or ARDX?

Summary

How does Ardelyx compare to CRISPR Therapeutics?

Do analysts prefer CRSP or ARDX?

Does the media favor CRSP or ARDX?

Is CRSP or ARDX more profitable?

Do institutionals and insiders hold more shares of CRSP or ARDX?

Which has more volatility and risk, CRSP or ARDX?

Which has better earnings & valuation, CRSP or ARDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX vs. The Competition

Ardelyx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools